82 related articles for article (PubMed ID: 19650002)
1. [PCSK9 - break through in the prevention and treatment of arteriosclerosis?].
Lewartowski B
Kardiol Pol; 2009 Jul; 67(7):782-6. PubMed ID: 19650002
[No Abstract] [Full Text] [Related]
2. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
Cao G; Qian YW; Kowala MC; Konrad RJ
Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):238-43. PubMed ID: 19075777
[TBL] [Abstract][Full Text] [Related]
3. What promise does PCSK9 hold?
Kastelein JJ; Fouchier SW; Defesche JC
J Am Coll Cardiol; 2005 May; 45(10):1620-1. PubMed ID: 15893177
[No Abstract] [Full Text] [Related]
4. [Anti-PCSK9 in coronary artery disease: genetic progress, therapeutic approaches].
Abifadel M; Ghaleb Y; Elbitar S; El Khoury P; Rabès JP; Varret M; Boileau C
Rev Prat; 2015 Mar; 65(3):326-7. PubMed ID: 26016189
[No Abstract] [Full Text] [Related]
5. JAMA PATIENT PAGE. PCSK9 Inhibitors for Treating High Cholesterol.
Jin J
JAMA; 2015 Dec; 314(21):2320. PubMed ID: 26624842
[No Abstract] [Full Text] [Related]
6. [PCSK9: a new gene involved in familial hypercholesteremia].
Lambert G; Costet P; Krempf M; Lalanne F
Med Sci (Paris); 2004 Dec; 20(12):1068-70. PubMed ID: 15581455
[No Abstract] [Full Text] [Related]
7. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.
Chen SN; Ballantyne CM; Gotto AM; Tan Y; Willerson JT; Marian AJ
J Am Coll Cardiol; 2005 May; 45(10):1611-9. PubMed ID: 15893176
[TBL] [Abstract][Full Text] [Related]
8. Molecular biology of PCSK9: its role in LDL metabolism.
Horton JD; Cohen JC; Hobbs HH
Trends Biochem Sci; 2007 Feb; 32(2):71-7. PubMed ID: 17215125
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
Costet P; Krempf M; Cariou B
Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
[TBL] [Abstract][Full Text] [Related]
10. [Monogenic hypercholesterolemias: new genes, new drug targets].
Mandel'shtam MIu; Vasil'ev VB
Genetika; 2008 Oct; 44(10):1309-16. PubMed ID: 19062528
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of PCSK9 function.
Lambert G; Charlton F; Rye KA; Piper DE
Atherosclerosis; 2009 Mar; 203(1):1-7. PubMed ID: 18649882
[TBL] [Abstract][Full Text] [Related]
12. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
[TBL] [Abstract][Full Text] [Related]
13. Protease variants, LDL, and coronary heart disease.
Tall AR
N Engl J Med; 2006 Mar; 354(12):1310-2. PubMed ID: 16554535
[No Abstract] [Full Text] [Related]
14. Beyond LDL cholesterol, a new role for PCSK9.
Akram ON; Bernier A; Petrides F; Wong G; Lambert G
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1279-81. PubMed ID: 20554949
[No Abstract] [Full Text] [Related]
15. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
Shan L; Pang L; Zhang R; Murgolo NJ; Lan H; Hedrick JA
Biochem Biophys Res Commun; 2008 Oct; 375(1):69-73. PubMed ID: 18675252
[TBL] [Abstract][Full Text] [Related]
16. [PCSK9, from gene to protein: a new actor involved in cholesterol homeostasis].
Abifadel M; Rabès JP; Boileau C; Varret M
Med Sci (Paris); 2006 Nov; 22(11):916-8. PubMed ID: 17101087
[No Abstract] [Full Text] [Related]
17. The mystery of PCSK9.
Attie AD
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1337-9. PubMed ID: 15297287
[No Abstract] [Full Text] [Related]
18. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
Lopez D
Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
[TBL] [Abstract][Full Text] [Related]
19. Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterol.
Wierzbicki AS
Curr Opin Lipidol; 2007 Apr; 18(2):227-9. PubMed ID: 17353672
[No Abstract] [Full Text] [Related]
20. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
